Clinical trial

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

NCT00395317

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-12-01

PhasePHASE2

Study timeline

Study start (unknown)2006-12-01Date precision: month

Registry last updated2012-04-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

PlaceboOTHER

Firategrast 150 mgDRUG

Firategrast 300 mgDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

Saint PetersburgRussia4 MadridSpain3 MoscowRussia3 PoznanPoland2 BarcelonaSpain1 WarsawPoland1 ValenciaSpain1 SevilleSpain1 MarseilleFrance1 OttawaOntario, Canada1 StrasbourgFrance1 LilleFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00395317 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.